Key Points
- Tobacco group Altria expects profit boost in the second half of 2026 from a U.S. tax rebate on increased cigarette imports and exports, known as ‘double duty drawback’.
- Altria just missed Q4 2025 profit estimates, reporting adjusted EPS of $1.30 versus forecast $1.32, though revenue hit $5.08 billion beating $5.02 billion expected.
- Shares fell around 2.8% despite full-year 2026 adjusted earnings guidance of $5.56 to $5.72 per share, midpoint above LSEG analysts’ $5.58 estimate.
- Duty drawback allows reclaiming federal excise taxes on domestic sales when exporting similar products overseas, even if exports were untaxed; rivals like British American Tobacco have used it.
- Altria, lacking overseas sales, partners with Korea’s KT&G for exports via contract manufacturing to capitalise.
- Altria finance chief Salvatore Mancuso, becoming CEO in May 2026, told Reuters: “it would be foolish not to take advantage of the provision and to remain at a competitive disadvantage.”
- Declining tobacco sales prompt focus on nicotine pouches like On!, facing rival market share losses; Bernstein analysts note “challenging picture”.
- Q4 domestic cigarette volumes down 7.9%, full-year 10%; industry down 8% adjusted.
- $1.3 billion non-cash impairment on e-vapor assets due to illicit products and slow FDA approvals.
- Returned $8 billion to shareholders in 2025 via dividends and repurchases.
- CEO Billy Gifford highlighted smoke-free alternatives over 50% of nicotine market; on! PLUS national rollout H1 2026.
Bengaluru (Cardiff Daily) January 30, 2026 – Tobacco group Altria, the maker of Marlboro cigarettes in the United States, expects its profit to receive a boost in the second half of 2026 by utilising a U.S. tax rebate on increased imports and exports of cigarettes, following a narrow miss on fourth-quarter 2025 profit estimates.
What is the Duty Drawback Provision?
Tobacco companies exporting products outside the United States have exploited a provision dubbed the ‘double duty drawback’ to recover federal excise taxes paid on domestically sold items. As reported by Emma Rumney and Angela Christy M of Reuters, this allows firms to reclaim duties on domestic cigarette sales upon exporting comparable products abroad, regardless of whether the exports incurred tax.
Altria previously could not benefit, unlike rivals such as British American Tobacco, owing to its absence of international cigarette sales. However, the company now leverages partnerships with foreign entities like Korea’s KT&G for contract manufacturing and exports.
In the earnings call, CEO Billy Gifford stated: “with the duty drawback, we’re looking to not be at a competitive disadvantage regarding that, and we’ll continue to look for opportunities to expand.”
Why Did Altria Miss Q4 2025 Profit Estimates?
Altria posted Q4 2025 adjusted earnings of $1.30 per diluted share, flat year-on-year and shy of the $1.32 consensus forecast, per Investing.com transcript coverage. Revenue reached $5.08 billion, topping the $5.02 billion expected, yet shares dropped 2.8% to around $61 pre-market, a 3.37% fall.
Full-year adjusted diluted EPS grew 4.4%, with smokable products delivering $11 billion adjusted OCI and margins up 1.8 points to 63.4%, driven by 8.4% net price realisation. Q4 smokable adjusted OCI fell 2.4%, margins contracting 0.8 points to 60.4% amid import-export investments.
CFO Sal Mancuso noted higher manufacturing costs from building capabilities at Richmond facility. Domestic cigarette volumes declined 7.9% in Q4 (9.5% adjusted), industry 6.5% adjusted.
How Will Duty Drawback Boost 2026 Profits?
Altria anticipates 2026 adjusted diluted EPS of $5.56-$5.72, implying 2.5%-5.5% growth from 2025’s $5.42 base, weighted to H2 as import-export ramps. Guidance factors $300-375 million capex for manufacturing/duty-drawback, limited illicit enforcement volume impact, no NJOY ACE return.
As per Reuters reporting by Emma Rumney and Angela Christy M, Salvatore Mancuso, incoming CEO in May, remarked to Reuters: “it would be foolish not to take advantage of the provision and to remain at a competitive disadvantage.”
Analyst Matt Smith of Stifel queried scope; Gifford replied it involves upfront investments moderating over time, positioning Richmond for international production.
Bernstein analysts, cited in Reuters, cautioned Altria faces a “challenging picture” despite drawback potential.
What Role Does KT&G Partnership Play?
Altria partners with KT&G for cigarette exports, enabling drawback access. A September 2025 MOU expands to nicotine pouches, wellness via Korea Ginseng Corp., and tobacco efficiencies.
Altria CEO Billy Gifford said: “We are excited to collaborate with KT&G and their strengths across innovative nicotine and non-nicotine products.” KT&G CEO Kyung-man Bang added it secures growth beyond cigarettes.
In call, analyst Bonnie Herzog of Goldman Sachs linked Basic promotions to KT&G ramp; Gifford separated decisions, stressing competitiveness.
What Challenges Hit New Products Like On!?
With cigarette sales waning, Altria pivots to On! nicotine pouches, but rivals erode share amid promotions. Competitor prices fell 3% sequentially, 12% YoY; on! rose 4% and 3%.
Helix’s on! shipped 44 million cans Q4 (177 million FY, +11%), retail share 7.7% Q4, 8.2% FY; oral share 29.6% Q4. on! PLUS (Mint, Wintergreen, Tobacco 6/9mg authorised) launches nationally H1 2026 post-FDA nods.
Gifford noted superior purchase intent, pouch comfort. Oral OCI down 4.6% Q4, margins -5 points to 64.5%.
E-vapor woes: $1.3 billion impairment on NJOY assets from illicit disposables (70% category), slow FDA, IP issues. Gifford: “proliferation of illicit disposable products… significant headwinds.”
Who Leads Altria’s Transition?
Salvatore Mancuso assumes CEO May 2026 from Billy Gifford; Heather Newman to CFO. Mancuso drives drawback strategy.
Gifford praised 2025 momentum: smoke-free >50% nicotine space, up 5 points. Returned $8 billion to shareholders; dividend up 3.9%, 60th in 56 years.
What Do Analysts and Market Say?
MarketBeat noted flat revenue YoY, leverage concerns. TipRanks: Q4 EPS miss, cigarette declines prompt downside.
Call Q&A: Stifel’s Smith on capex (import/export primary, disciplined); Goldman’s Herzog on Basic (independent of drawback); Morgan Stanley’s Serotta on youth smoking (vision-focused), on! PLUS premium pricing.
